This memorandum addresses patient access to experimental treatments, including access to clinical trials, participation in the U.S. Food and Drug Administration’s Expanded Access Program, and access to treatments under Colorado’s Right to Try Act. Additionally, this memorandum discusses “’Right to Try” legislation in other states and in the U.S. Congress. Finally, the memorandum addresses insurance coverage of experimental treatments administered both within and outside of clinical trials.